Pro7-Arg*-Arg9-Pro1*-Tyr1 I-Ilel2-Leu' 3 , fulfils a number of criteria for a neurotransmitter or neurohormone in the central nervous system (see Nemeroff et al., 1980; . Thus it can be shown that NT-like immunoreactivity is concentrated in nerve endings from which it can be released in a calcium-dependent fashion (Uhl & Snyder, 1976) and that regions rich in NT-like immunoreactivity Abbreviation used. N T , neurotensin. also contain NT-binding sites which may possibly represent physiological receptors for N T (Goedert er al., 1984) . However, despite this evidence of release and receptor binding there is no identified mechanism for inactivation of NT, although reports for other peptides (enkephalin and substance P) have suggested that relatively specific peptidases might exist (Schwartz et al., 1981; Lee et al., 1981) . We investigated the ability of brain or synaptic membranes to degrade NT, and using inhibitors and antibodies directed against known peptidases have attempted to determine the enzymes that may be involved in NT degradation at the synaptic cleft.
Initial studies of NT degradation by extensively washed brain or synaptic membranes revealed that C-terminal immunoreactivity was lost much more rapidly than Nterminal immunoreactivity (Emson et al., 1982) . This result together with other studies by McDermott et al. (1982) revealed that the biologically active portion of the N T sequence (the C-terminus) was destroyed first by membrane fractions. In order to follow up these observations, washed rat brain membranes were treated with 1% Triton X-100 at 37°C for 1 h and the supernatant containing all the NT- 
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BIOCHEMICAL SOCIETY TRANSACTIONS degrading activity was separated by chromatography on DEAE-cellulose and hydroxyapatite columns (Emson et al., 1982) .
Incubation of fractions containing NT-degrading activity with N T and synthetic substrates for known peptidases revealed the presence of an endopeptidase-rich fraction (fraction 11) and a further fraction containing both prolyl endopeptidase (EC 3. 4.21.26 ) and angiotensin converting enzyme (EC 3.4.15.1) activity (fraction I) (Emson et al., 1982) . As all these enzymes might contribute to the degradation of NT in uiuo, it was necessary to carry out a more detailed study using known inhibitors of the enzymes which may be involved [prolyl endopeptidase (2-Pro-prolinal), angiotensin-converting enzyme (captopril) and endopeptidase-24.11 (thiorphan)] to determine if any of these enzymes might be involved (Cheder et al., 19836, 1984) . Our results are summarized in Fig. 1 and we suggest that the main inactivating cleavages of NT involve endopeptidase-24.11 and a further unidentified endopeptidase (not sensitive to captopril or thiorphan) (Cheder et al., 19836, 1984) . Angiotensin-converting enzyme is involved in further degradation of some of the fragments resulting from the endopeptidase action [especially the formation of NT-(1-8) from NT-(1-lo)], and may also contribute slightly to NT inactivation by cleavage at the Tyrl'-Ile'Z bond. Similarly, enzymes related to endopeptidase A (Camargo el al., 1983) or the metallopeptidase described by Orlowski and colleagues (Orlowski et al., 1983) may also degrade NT to yield NT-( 1-8) and NT-(9-13) fragments by cleaving at the Args-Argy bond. However, it should be pointed out that neither endopeptidase A nor the enzyme described by Orlowski et a/. ( I 983) would remove NT biological activity which resides in the C-terminal (9-1 3) sequence. The tyrosine at position 1 I in the sequence seems to be critical for biological activity and degradation, so that it was particularly interesting to find that D-amino acid analogues of NT such as [D-Phe'IlNT are resistant to degradation in uirro and in uiuo and have prolonged biological activity in rho (Cheder et al., 1983~) .
The results of our study indicate that brain NT can be inactivated and degraded by several different enzymes in uitro (and presumably in uiuo), and it should be stressed that no one specific enzyme ('neurotensinase') is likely to be involved in its degradation. Knowledge of the key position of the Tyrl in degradation of NT in uitro and in uiuo should also facilitate the design of active stable neurotensin analogues which will further the study of the physiological role of this peptide.
